This study provides an example of downregulating endogenous gene expression in mammalian cells via the use of IDT predesigned Dicer-substrate siRNAs (DsiRNAs). By effectively knocking down the expression level of endogenous gene PEBP1 in both human and mouse cell lines, the researchers show that lowered expression of PEBP1 is associated with decreased sensitivity to ferroptosis, a form of programmed cell death that is pathogenic to several acute and chronic diseases.
A review of the use of aptamers to target siRNAs to HIV-1 proteins.
Efficient, noncovalent binding of Dicer-substrate siRNAs (DsiRNAs) to an aptamer for effective in vivo knockdown of target mRNAs and potent inhibition of HIV-1 replication.
Use of DsiRNAs to inhibit TNF-ɑ secretion in the study of inflammatory diseases. Data shows greater effectiveness of 27mer DsiRNAs than 21mers.
Bladder cancer cells pre-treated with Dicer-substrate siRNA (DsiRNA) against Ki-67, a DNA-binding protein associated with cell proliferation proliferation, promotes cell cycle arrest and enhances curcumin-induced apoptosis.
Use of DsiRNAs to inhibit viral replication of metapneumovirus in vitro and in vivo. The authors report highly specific inhibition achieved without induction of cytokines or off-target effects.
Use of an RNA aptamer–siRNA chimera that triggers sequence-specific degradation of HIV RNAs to suppress HIV-1 replication and prevent CD4+ T cell depletion in humanized mice.
An IDT MiniGene expressing wild-type survival motor neuron from SMN2, and a second SMN2 MiniGene with a silent mutation in the siRNA recognition sequence, were used to study the effects of siRNA knockdown, and rescue, of SMN1/2 on gene splicing. IDT DsiRNA Duplexes were also used for the siRNA knockdown experiments.
A review summarizing the use of cell-internalizing aptamers to deliver siRNAs to target cells. Highlights the optimization and improvement of aptamer-targeted siRNAs for clinical translation.
Dicer-substrate RNA (DsiRNA) is used to target physiological pain modulators in animal models for in vivo pain research.
Use of a novel CpG-motif oligonucleotide delivery tool to deliver anti-STAT3 DsiRNA to TLR9-positive cells, where Dicer cleavage releases the mature siRNA from the CpG ligand.
Use of aptamers and aptamer–siRNA chimeras to inhibit HIV-1 replication and infectivity in cultured human CEM T cells and primary blood mononuclear cells.